Two sides of the same coin: Balancing the risks of rejection and infection in transplanted Fontan patients with dysregulated pretransplant immune function.
- Resource Type
- Article
- Authors
- Wright, Lydia K.; Gajarski, Robert J.
- Source
- Pediatric Transplantation. Aug2023, Vol. 27 Issue 5, p1-2. 2p.
- Subject
- *KIDNEY transplantation
*HEART transplant recipients
*PROTEIN-losing enteropathy
- Language
- ISSN
- 1397-3142
These studies highlight well a fundamental challenge that remains a critical element in the care of the post-transplant Fontan patient: how do we tailor immunosuppression to minimize both post-transplant infection and rejection in these children with such altered pretransplant immunophenotypes? Abbreviations AMR antibody-mediated rejection ATG antithymocyte globulin CHD congenital heart disease DSAs donor-specific antibodies PLE protein-losing enteropathy Since its introduction in the 1970s, the Fontan palliation for single ventricle congenital heart disease (CHD) has improved survival for thousands of affected children, and a growing number are living into adulthood.[1] There are myriad long-term consequences of this physiology, and those with failing Fontan physiology comprise an increasing number of pediatric and young adult heart transplant recipients. [Extracted from the article]